{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:31:29Z","timestamp":1788546689890,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40123-024-00949-4","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T12:01:39Z","timestamp":1714046499000},"page":"1693-1701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease Following LASIK"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-0465","authenticated-orcid":false,"given":"Tanner J.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Risbrudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Stofferahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"1","key":"949_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jtos.2018.11.003","volume":"17","author":"JA Gomes","year":"2019","unstructured":"Gomes JA, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: a review. Ocul Surf. 2019;17(1):9\u201319.","journal-title":"Ocul Surf"},{"issue":"2","key":"949_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","volume":"14","author":"M McDonald","year":"2016","unstructured":"McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016;14(2):144\u201367. https:\/\/doi.org\/10.1016\/j.jtos.2015.11.002.","journal-title":"Ocul Surf"},{"issue":"3","key":"949_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008.","journal-title":"Ocul Surf"},{"issue":"2","key":"949_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/ICO.0000000000003090","volume":"42","author":"D Zhu","year":"2023","unstructured":"Zhu D, Gupta RR, Stein RL, et al. Randomized prospective evaluation of microblepharoexfoliation blephex as adjunctive therapy in the treatment of Chalazia. Cornea. 2023;42(2):172\u20135. https:\/\/doi.org\/10.1097\/ICO.0000000000003090.","journal-title":"Cornea"},{"issue":"12","key":"949_CR5","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.ophtha.2023.07.009","volume":"130","author":"JP Tao","year":"2023","unstructured":"Tao JP, Shen JF, Aakalu VK, et al. Thermal pulsation in the management of meibomian gland dysfunction and dry eye: a report by the American academy of ophthalmology. Ophthalmology. 2023;130(12):1336\u201341. https:\/\/doi.org\/10.1016\/j.ophtha.2023.07.009.","journal-title":"Ophthalmology"},{"issue":"3","key":"949_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/jop.2019.0092","volume":"36","author":"D Schmidl","year":"2020","unstructured":"Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154\u201361.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"949_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/j.jcrs.0000000000000844","volume":"48","author":"K Donaldson","year":"2022","unstructured":"Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022;48(5):623\u20139.","journal-title":"J Cataract Refract Surg"},{"issue":"5","key":"949_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/eop.11.56","volume":"6","author":"RM Shtein","year":"2011","unstructured":"Shtein RM. Post-LASIK dry eye. Expert Rev Ophthalmol. 2011;6(5):575\u201382. https:\/\/doi.org\/10.1586\/eop.11.56.","journal-title":"Expert Rev Ophthalmol"},{"key":"949_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4903831","volume":"2018","author":"E Cohen","year":"2018","unstructured":"Cohen E, Spierer O. Dry eye post-laser-assisted in situ keratomileusis: major review and latest updates. J Ophthalmol. 2018;2018:1\u20139.","journal-title":"J Ophthalmol"},{"issue":"1","key":"949_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0002-9394(01)00959-x","volume":"132","author":"I Toda","year":"2001","unstructured":"Toda I, Asano-Kato N, Komai-Hori Y, Tsubota K. Dry eye after laser in situ keratomileusis. Am J Ophthalmol. 2001;132(1):1\u20137. https:\/\/doi.org\/10.1016\/s0002-9394(01)00959-x.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"949_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jtos.2018.11.002","volume":"17","author":"G Dieckmann","year":"2019","unstructured":"Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease\u2014past, present, and future. Ocul Surf. 2019;17(1):20\u20137.","journal-title":"Ocul Surf"},{"issue":"2","key":"949_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtos.2019.09.006","volume":"18","author":"GR Pattar","year":"2020","unstructured":"Pattar GR, Jerkins G, Evans DG, et al. Symptom improvement in dry eye subjects following intranasal tear neurostimulation: results of two studies utilizing a controlled adverse environment. Ocul Surf. 2020;18(2):249\u201357. https:\/\/doi.org\/10.1016\/j.jtos.2019.09.006.","journal-title":"Ocul Surf"},{"issue":"4","key":"949_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","volume":"129","author":"D Wirta","year":"2022","unstructured":"Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022;129(4):379\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.004.","journal-title":"Ophthalmology"},{"key":"949_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","volume":"24","author":"H Quiroz-Mercado","year":"2022","unstructured":"Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, Henry E, Nau JA. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study. Ocul Surf. 2022;24:15\u201321. https:\/\/doi.org\/10.1016\/j.jtos.2021.12.007.","journal-title":"Ocul Surf"},{"issue":"10","key":"949_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","volume":"41","author":"D Wirta","year":"2022","unstructured":"Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea. 2022;41(10):1207\u201316. https:\/\/doi.org\/10.1097\/ICO.0000000000002941.","journal-title":"Cornea"},{"issue":"3","key":"949_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ajo.2005.10.006","volume":"141","author":"CS De Paiva","year":"2006","unstructured":"De Paiva CS, Chen Z, Koch DD, et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol. 2006;141(3):438\u201345. https:\/\/doi.org\/10.1016\/j.ajo.2005.10.006.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"949_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2023.1109","volume":"141","author":"MK Shoji","year":"2023","unstructured":"Shoji MK, Gutkind NE, Meyer BI, et al. Multidrug-resistant pseudomonas aeruginosa keratitis associated with artificial tear use. JAMA Ophthalmol. 2023;141(5):499\u2013500. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.1109.","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00949-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-00949-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-00949-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T12:32:27Z","timestamp":1716294747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-00949-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-00949-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"21 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Greenwood reports research funding from Viatris, Inc. All relevant authors including Drs. Ferguson, Messer, Risbrudt\u00a0and Stofferahn have no relevant financial disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the WCG Insitutional Review Board (20215075). All procedures conducted were in accordance with the Aspire IRB and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained for each subject prior to the study. This was a prospective, randomized, controlled, study performed at a single site (Fargo, ND) in the US (NCT05082974).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}